PEAQX tetrasodium salt

Pricing Availability   Qty
Description: Potent and GluN2A-selective NMDA antagonist
Chemical Name: [[[(1S)-1-(4-Bromophenyl)ethyl]amino](1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)methyl] phosphonic acid tetrasodium salt
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (5)

Biological Activity for PEAQX tetrasodium salt

PEAQX tetrasodium salt is a potent NMDA receptor antagonist (IC50 = 8 nM). Exhibits >100-fold selectivity for hGluN2A (formally hNR2A) containing receptors over hGluN2B (hNR2B). Anticonvulsant in vivo.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Technical Data for PEAQX tetrasodium salt

M. Wt 542.14
Formula C17H13BrN3Na4O5P
Storage Store at -20°C
Purity ≥98% (HPLC)
PubChem ID 76900415
InChI Key QBVOZIDKUFSQIL-LPOFVUTESA-J
Smiles C[C@@H](C3=CC=C(Br)C=C3)NC(P([O-])([O-])=O)C1=C2C(N=C([O-])C([O-])=N2)=CC=C1.[Na+].[Na+].[Na+].[Na+]

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for PEAQX tetrasodium salt

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 5.42 10 with gentle warming

Preparing Stock Solutions for PEAQX tetrasodium salt

The following data is based on the product molecular weight 542.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 18.45 mL 92.23 mL 184.45 mL
0.5 mM 3.69 mL 18.45 mL 36.89 mL
1 mM 1.84 mL 9.22 mL 18.45 mL
5 mM 0.37 mL 1.84 mL 3.69 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for PEAQX tetrasodium salt

Certificate of Analysis / Product Datasheet
Select another batch:

References for PEAQX tetrasodium salt

References are publications that support the biological activity of the product.

Auberson et al (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg.Med.Chem.Lett. 12 1099 PMID: 11909726


If you know of a relevant reference for PEAQX tetrasodium salt, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: PEAQX tetrasodium salt, PEAQX tetrasodium salt supplier, NVP-AAM, 077, anticonvulsants, potent, selective, NMDA, subtype, antagonists, antagonism, 459836-30-7, 2102348-87-6, Receptors, 5018, Tocris Bioscience

2 Citations for PEAQX tetrasodium salt

Citations are publications that use Tocris products. Selected citations for PEAQX tetrasodium salt include:

Pavel et al (2021) Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats. Pharmaceutics 13 PMID: 33808912

Eckart D et al (2022) Ca2+ signaling in postsynaptic neurons: Neuroplastin-65 regulates the interplay between plasma membrane Ca2+ ATPases and ionotropic glutamate receptors. Cell Calcium 106 102623 PMID: 35853264


Do you know of a great paper that uses PEAQX tetrasodium salt from Tocris? Please let us know.

Reviews for PEAQX tetrasodium salt

There are currently no reviews for this product. Be the first to review PEAQX tetrasodium salt and earn rewards!

Have you used PEAQX tetrasodium salt?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.